Abstract: By allowing for direct injection of urine, liquid chromatography-tandem mass spectrometry (LC-MS-MS) with atmospheric-pressure chemical ionization has proven to be useful for analysis of drugs of abuse in human urine. The purpose of this study was to evaluate this technique by direct screening for 23 different substances (phenylethylamines, hypnotics, and N-benzylpiperazine) in urine samples. It was possible to achieve lower detection limits compared with commercial immunochemical methods. There was a linear response for all analytes with an intraday coefficient of variation of about 16%, and the gradient elution gave a variability in relative retention time of about 1%. Positive results were confirmed by reanalysis including sample preparation by solid-phase extraction. Among the 529 authentic urine samples analyzed, 35 samples were screened positive for phenylethylamines, and 20 for hypnotics. Of these, 23 (66%) samples were confirmed to be positive for phenylethylamines, and 11 (55%) for hypnotics. This study demonstrates that LC-MS-MS is a valuable complement to immunochemical screening analysis, especially for substances for which immunochemical methods are not yet available or when an increased sensitivity is needed.
I
n urine testing for drugs of abuse the most common and costeffective approach has been to perform a preliminary screening by an immunochemical technique and to confirm positive results by gas chromatography-mass spectrometry. Although many advantages exists for immunochemical assays, one limitation is the restricted number of analytes covered. It is time consuming to develop immunoassays for new analytes, and therefore other techniques such as mass spectrometry (MS) can be used as an alternative to immunochemical screening. 1, 2 By using solid-phase extraction (SPE) followed by mass spectrometry, it is possible to obtain a high sample throughput (1000 samples per 12 hours). 1 Recent experience has shown that chromatographic separation from matrix components is preferable to minimize ion supression. 3 The use of rapid chromatography is the most promising approach for direct analysis of urine by liquid chromatography-tandem mass spectrometry (LC-MS-MS). This technique was recently demonstrated to be a viable alternative to immunochemical screening for the analysis of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in clinical urine samples. 4 The LC-MS-MS method offered lower cutoff limits than the immunochemical alternative as well as providing more specific information regarding the identity of a detected compound. Another advantage is the greater freedom in the choice of analytes included in the assay.
There are an increasing number of substances that may become subjected to abuse. For example, several substances other than MDMA, such as 2,5-dimethoxy-4-(n)-propylthiophenylethylamine (2-CT7), 4-methylthioamphetamine (4-MTA), 4-methoxyamphetamine (PMA), and 4-methoxymethamphetamine (PMMA), have been identified in "ecstasy" tablets. 5 Furthermore, a death caused by 4-bromo-2,5-dimethoxyamphetamine (DOB) has been reported, 6 4-bromo-2,5-dimethoxyphenylethylamine (2-CB) has been identified in powder and tablets, 5, 7, 8 and 4-MTA was identified as the single drug in a poisoning in Great Britain. 9 Recently, the identification of N-benzylpiperazine in a forensic autopsy case added yet another group of chemical structures to the list of abused drugs.
10 N-Benzylpiperazine is a stimulant with amphetamine-like effects. [11] [12] [13] Other substances with the potential of being abused are new hypnotic drugs such as zopiclone, zolpidem, and zaleplon. They have pharmacologic effects similar to benzodiazepines but were initially believed to have low abuse potential. However, abuse of these new medicaments has now been reported, including reports on the development of tolerance, withdrawal, and dependence. [14] [15] [16] There is no commercial immunochemical screening method available for any of these substances.
The aim with this study was to further evaluate the potential of using direct-injection LC-MS-MS for screening of drugs of abuse in clinical urine samples. In total, 23 different substances were covered by the screening procedure.
MATERIAL AND METHODS

Chemicals
3,4-Methylenedioxy-N-methylamphetamine (MDMA), 3,4-methylenedioxyamphetamine (MDA), 1-(4-bromo-2,5-dimethoxyphenyl)-2-ethaneamine (2-CB), N,N-dimethyl-MDA, N-hydroxy-MDA, N,N-dimethyl-1-phenyl-2-ethaneamine, 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA), and N-benzylpiperazine were obtained from Sigma (St. Louis, MO). 2-Methylamino-1-(3,4-methylenedioxyphenyl)-butane (MBDB), N-ethyl-3,4-methylenedioxyamphetamine (MDEA), and 3,4-methylenedioxy-N-propylamphetamine (MDPA) were purchased from Alltech (Deerfield, IL). 4-Hydroxy-3-methoxy-N-methylamphetamine (HMMA) was supplied by Radian (Austin, TX). MDMA-D 5 (internal standard) was purchased from Cerilliant (Austin, TX). 2,5-Dimethoxy-4-bromoamphetamine (DOB), 2,5-dimethoxy-4-iodoamphetamine (DOI), and 1-phenyl-2-butaneamine were obtained from Sigma/RBI (St. Louis, MO). 2,4,5-Trimethoxyamphetamine (TMA-2) and 3,4-ethylenedioxyamphetamine (EDA) were obtained from Mr. Tomas Lilius, Stockholm, Sweden. Zopiclone, its metabolites nor-zopiclone and zopiclone-N-oxide, and RP29481 (internal standard) were a gift from Rhône-Poulenc Rorer (Vitry-Albertville, France). Zolpidem and its metabolites, 1 and 2, 17 were kindly provided by Synthélabo Recherche (Bagneux Cedex, France). Zaleplon was a gift from Wyeth-Ayerst Research (Princeton, NJ). Methanol (HPLC grade), isopropanol (HPLC grade), acetic acid (p.a., pro analysi), and methylene chloride (HPLC grade) were obtained from J. T. Baker (Deventer, Holland). Formic acid, ammonium acetate, sodium carbonate, and ammonium hydroxide (25%) were all of p.a. quality and purchased from Merck (Darmstadt, Germany).
Apparatus
The LC system consisted of a vacuum degasser (Waters, Milford, MA), a Series 200 mixer, autosampler, and micropump (Perkin Elmer, Norwalk, CT), and a column oven (Kontron, Zürich, Switzerland).
A triple-quadrupole mass spectrometer was used for detection, both in the screening and confirmation analysis (Sciex 2000 from Applied Biosystems, MDS Sciex, Concord, Ontario, Canada). The system was controlled via Analyst 1.1 software (PE Sciex, Concord, Ontario, Canada). Nitrogen gas was used as collision gas to induce fragmentation of the pseudomolecular ions. The mass spectrometer was connected to the LC via an atmospheric pressure chemical ionization (APCI) interface kept at 450°C. The interface was set to positive ion mode, and the monitored ion transitions from the pseudomolecular ions are given in Table 1 .
Screening Analysis
The mobile phase used for screening analysis consisted of 10 mM ammonium acetate and methanol. A gradient was used starting at 5% methanol and increasing to 80% between 0.1 and 1 minute, followed by 5% methanol for 5 minutes. The flow rate was 400 µL/min. The analytical column was a HyPURITY Advance 30 × 2.1 mm, 3-µm particle size, with a 10 × 2 mm integrated guard column (ThermoQuest, Runcorn, Cheshire, U.K.). The column temperature was 40°C. The dead volume of the gradient system was approximately 2 minutes.
A 10-µL aliquot of the urine sample was mixed with 90 µL of ultrapure water containing MDMA-D 5 (0.11 µg/mL), and 10 µL was injected into the LC-MS-MS system.
Confirmation Analysis
All preliminary positive results from the screening analysis were confirmed by a second analysis that included a sample preparation. The LC system was modified, but the mass spectrometric settings were identical to those used in the screening analysis. The confirmation analysis was separated into two procedures, one for the phenylethylamines and Nbenzylpiperazine (System 1) and one for the hypnotics (System 2).
System 1
The confirmation analysis for the PEAs and N-benzylpiperazine used a HyPURITY Advance column (125 × 2.1 mm, 3-µm particle size), with a 10 × 2 mm integrated guard column, kept at 40°C. The mobile phase contained 10 mM ammonium acetate and methanol. A gradient was used starting at 5% methanol and increasing to 80% between 0.1 and 10 minutes, followed by 5% methanol for 20 minutes. The flow rate was 200 µL/min. A support flow at 200 µL/min containing 10 mM ammonium acetate and 5% methanol was added postcolumn, before the interface to the mass spectrometer.
After testing of different solid-phase materials, it was concluded that an end-capped C 18 column together with basic pH for application of the sample generated high recovery and clean extracts for the phenylethylamines and N-benzylpiperazine. Using end-capped 100-mg C 18 solid-phase extraction (SPE) cartridges from Isolute (Hengoed, Mid Glamorgan, U.K.) the samples were extracted manually using an IST VacMaster and the maximum flow rate was 1 mL/min. The columns were conditioned with 3 mL of methanol, 3 mL of distilled water, and 3 mL of 100 mM sodium carbonate buffer. A 1-mL aliquot of urine was mixed with 1 mL of sodium carbonate buffer and MDMA-D 5 (0.0 µg in 50 µL ultrapure water), applied to the column, and allowed to flow through by gravity. The cartridge was then washed with 2 mL of sodium carbonate buffer and 1 mL of 100 mM acetic acid. Before elution the columns were dried by applying vacuum for 1 minute. Analytes were eluted with 2 mL of methylene chloride:isopropanol (80:20,vol/vol) containing 2% ammonium hydroxide. For the elution of N,N-dimethyl-1-phenyl-2-ethaneamine, the elution was performed in two steps. First 2 mL of methylene chloride: isopropanol (80:20,vol/vol) containing 2% ammonium hydroxide was applied, and second 2 mL of methanol. Both fractions were collected in the same tube. The extracts were evaporated to dryness with nitrogen at 40°C, reconstituted in 200 µL 10 mM ammonium acetate containing 5% methanol, and 10 µL was injected into the LC-MS-MS system.
System 2
The mobile phase for confirmation of hypnotics contained 10 mM formic acid (pH 3.7) and methanol. The column used was a HyPURITY Advance 30 × 2.1 mm, 3-µm particle size, with a 10 × 2 mm integrated guard column. The column temperature was 40°C. A gradient was used starting at 5% methanol and increasing it to 80% between 0.1 and 1 minute, followed by 5% methanol for 5 minutes. The flow rate was set to 400 µL/min.
Sample preparation for confirmation of the hypnotics was performed as described previously with minor modification. 18 For the elution of zolpidem and its metabolites, the elution was performed in two steps. First 2 mL of methylene chloride:isopropanol (80:20, vol/vol) containing 2% ammonium hydroxide was applied, and second 2 mL of methanol. Both fractions were collected in the same tube. The samples were reconstituted in 200 µL 10 mM formic acid (pH 3.7) containing 5% methanol, and 10 µL was injected into the LC-MS-MS system.
Criteria for Detection in the Screening Analysis
In the screening analysis, the response of the analytes was tested by preparing a standard curve of blank urine spiked with typically three to six different concentrations starting at cutoff; the concentrations were grouped close to the cutoff levels to aid the determination of the cutoff levels. The cutoff levels for the analytes were defined as the concentration where the signal-to-noise ratio was greater than or equal to 3 (S/N Ն 3). Because the analytic sensitivity could vary slightly (∼2 to 5-fold) between runs, the higher concentration was chosen as the cutoff level. A sample was considered potentially positive if the concentration was above the cutoff level (Table 2) , and the relative retention time was within ±5% for a urine sample spiked with standard. MDMA-D 5 was used only for calculating the relative retention time.
Criteria for Identification in the Confirmation Analysis
For the confirmation analysis, single-point calibration was performed by triplicate analysis of spiked samples containing 0.8-4.4 µg/mL of the analytes. Control samples at two levels, one higher than the calibrator and one close to the cutoff level (Table 2) , were analyzed at least every 15th urine sample. A sample was considered positive if the concentration was above the cutoff level (Table 2 ) and the relative retention time was within ±1% for a urine sample spiked with standard. MDMA-D 5 was used only for calculating the relative retention time.
Method Validation
The standard deviation (SD) and coefficient of variation (CV) were calculated for both intra-(N = 10) and interday (N = 8) variation. They were determined in blank urine spiked to 0.1 µg/mL for MDEA, MDPA, MDMA, MDA, HMMA, DOB, DOI, 2,5-DMA, 2-CB, N,N-dimethyl-MDA, N,Ndimethyl-1-phenyl-2-ethaneamine, and 1-phenyl-2-butyleamine to 50 ng/mL for EDA, MBDB, and TMA-2 to 202 ng/mL for zopiclone-N-oxide, 169 ng/mL for zolpidem metabolites 1 and 2, 19 ng/mL for zopiclone and nor-zopiclone, to 15 ng/mL for zolpidem and zaleplon and 8.8 ng/mL for Nbenzylpiperazine. The response of the analytes was assessed for each batch of samples. Chromatographic stability was
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The stability of the analytes was tested in 100 authentic urine samples found negative for all the analytes. After pH measurement (5.0-7.9), they were placed on ice and spiked with a standard solution containing all analytes, prepared from negative urine. The final concentration in the authentic urine samples was 500 ng/mL (phenylethylamines), 88 ng/mL (Nbenzylpiperazine), and 150-200 ng/mL (hypnotics), and the total amount of organic solvents was <1%. Each sample was divided into two aliquots; one was frozen immediately, and the other kept in the dark at room temperature for 4 days before being frozen. Subsequently, the urine samples were analyzed in sequence using the screening methodology.
Urine Samples
Urine samples from suspected drug users were randomly selected from the routine flow of clinical samples sent to the hospital laboratory for the analysis of drugs of abuse. In total 529 samples were analyzed. This project was approved by the ethics committee at Karolinska Institutet (Dnr KI 00-236).
RESULTS AND DISCUSSION
Performance of the Screening Method
The cutoff levels applied are listed in Table 2 together with the intraday coefficient of variation (CV). The CV ranged from 7% to 33%. The interday CV was determined for 6 substances and varied between 15 and 31% ( Table 2 ). This level of imprecision was high as compared with immunochemical screening methodologies, where the CVs usually are below 10%. However, these methods work at much higher cutoff lev- Screening analysis. List of cutoff, standard deviation, and intraday variation CV(%) for the screening analysis. The CV was determined at 100 ng/mL for the PEAs (except for EDA, MBDB and TMA-2, which were determined at 50 ng/mL), ∼20 ng/mL for zopiclone, norzopiclone, zolpidem, and zaleplon, ∼200 ng/mL for zopiclone-N-oxide and zolpidem metabolites 1 and 2, and at 9 ng/mL for N-benzylpiperazine). Interday variation was determined at cutoff.
b
Confirmation analysis. List of cutoff, recovery (calculated at 1000 ng/mL for the PEAs, 300-400 ng/mL for the hypnotics, 3400 ng/mL for zolpidem metabolite 2, and 176 ng/mL for N-benzylpiperazine) and CV(%) for the confirmation analysis. Data of the recovery of zopiclone and its metabolites have already been published. 17 Ther
Multicomponent Screening for Drugs of Abuse els. To improve the precision of the method, analyte-specific deuterated analogues might be needed as internal standards as well as considering higher cutoff levels. Although the imprecision is high for some analytes, the detectability observed in the control samples was close to 100%. Only for DOI there were difficulties with the detectability. The method produced linear response with a coefficient of correlation greater than 0.98 for all analytes. Selected representative chromatograms obtained with spiked samples and positive authentic urine samples are shown in Figures 1, 2 and 3 . . The theoretical capacity of the method was about 200 samples in 24 hours. In practice, however, the capacity for one analyst is less than half of this when time for data analysis and maintenance of the equipment is included. Thus, increased automation is required for the preparation of samples as well as for data analysis. The Analyst software of the Sciex 2000 instrument did not allow for efficient evaluation of large amounts of chromatographic screening data. One strategy to minimize the time needed for evaluation could be to introduce a possibility in the software to enable it to exclude negative samples. This would leave fewer samples for visual evaluation.
Chromatographic stability is necessary for reliable detection of unknown substances. The CV for the relative retention time of control samples ranged from 0.3 to 3.8%. Two compounds (TMA-2 and DOI) showed CVs >3%, and the others <2%. DOI was generally the most problematic analyte and on one occasion, it was undetectable during a complete batch of samples (∼100 samples, analyzed overnight). DOB, 2-CB, and zolpidem also showed tendencies of variable retention time. The reason for this may be that they eluted late in the chromatogram, when the mobile phase gradient was completed and the column had started to equilibrate. The variation in retention time sometimes generated problems in the evaluation of a possibly positive sample. This could probably have been overcome by using more suitable internal standards for each substance, such as their deuterated analogues. However, at the time, MDMA-D 5 was the only deuterated standard available for our analytes. Another possibility is to modify the gradient. This has recently been confirmed experimentally by prolonging the plateau by 30 seconds with 80% methanol.
APCI was chosen over electrospray ionization because it initially was found to give improved sensitivity for both phenylethylamines and the hypnotics. It is likely that this choice also helped to increase the robustness of the method by a decreased effect of matrix components on the signal.
4,19
Solid-Phase Extraction
Solid-phase extraction (SPE) was used to prepare the urine samples for the confirmation analysis. The recoveries ranged between 76% and 126% for the phenylethylamines and N-benzylpiperazine (Table 2 ). This is in line with another study in which a recovery of at least 70% was obtained for different phenylethylamines using SPE. 20 For N,N-dimethyl-1-phenyl-2-ethaneamine, the elution included methanol, which improved the recovery by 75%.
The extraction method used for the hypnotics has been described earlier. 18 The routine performed well for all hypnotics (Table 2) . However, an extra elution step with methanol was needed to extract the metabolites of zolpidem. It improved the recovery by from 55% and 85% to 104% and 110% for metabolites 1 and 2, respectively. For zolpidem, there was no improvement of the recovery from using the extra elution step with methanol.
Performance of the Confirmation Method
The method produced linear response, with coefficients of correlation greater than 0.99 for all analytes. The cutoff levels for the confirmation analysis are listed in Table 2 . The confirmation analysis was typically 10 to 100 times more sensitive than the screening analysis because of the 5-fold concentration and reduced background signal. The problems with variable retention times in the screening analysis were not observed in the confirmation analysis.
Clinical Samples
During the validation study, 529 urine samples were analyzed in nine batches. Thirty-five samples screened positive for PEAs and N-benzylpiperazine (except 1-phenyl-2-butylamine), and 20 for hypnotics. Of these, 23 (66%) were confirmed positive for PEAs (MDMA and MDA only), and 11 (55%) for hypnotics (zopiclone and zolpidem). An example of a urine specimen being positive for zolpidem is shown in Figure 1B ,D. Another sample, positive for MDMA, is shown in Figure 2C ,D,G,H.
There was high degree of false-positive samples in the screening analysis. This could easily be solved by simply increasing the cutoff level to a minimum value of 200 ng/mL, after which 25 samples (21 confirmed, 84%) would have Multicomponent Screening for Drugs of Abuse screened positive for PEAs (except 1-phenyl-2-butylamine) and 11 (10 confirmed, 91%) for hypnotics. Thus, approximately 10% of the true positive samples had been missed using a higher cutoff level. Because this methodology will be used in a project aimed at studying the prevalence of these analytes in a population, the use of low cutoff levels is preferred to optimize sensitivity.
In the ion transition chromatograms it was common to observe other peaks than the analyte investigated. This made it necessary to use the relative retention time as a criterion for detection. In addition, many specimens showed a chromatographic interference with 1-phenyl-2-butylamine, which made it necessary to raise the cutoff to 0.5 µg/mL. The occurrence of chromatographic interferences demonstrates the importance of using relative retention time as a criterion for the detection of an analyte.
Analyte Stability in Urine
The stability of the analytes was assessed in authentic urine samples. After storage for 4 days at room temperature, no decline was observed (<6%) for any of the analytes except for zopiclone and its metabolites, nor-zopiclone and zopiclone-Noxide, which were found to be unstable at pH Ն 6.5 (results not shown). After 4 days at room temperature in a urine sample with pH above 7.5, zopiclone and its metabolites were almost undetectable. This pH-dependent instability has been described earlier. 18 These findings point at the need for careful handling of urine samples when analyzing zopiclone and its metabolites. The samples need to be analyzed within 2 days after sampling unless they are frozen or refrigerated.
CONCLUSIONS
Direct analysis of urine by LC-MS-MS is useful for screening of drugs of abuse. In combination with an APCI ion source, it generates reliable results and has the potential to be rapid and simple to use. The robustness of the methodology was demonstrated by analyzing authentic urine samples. Many different analytes can be analyzed simultaneously with high sensitivity, and there is the potential of quickly including new analytes. In addition to the selectivity provided by ion transition, chromatographic criteria needs to be carefully optimized to match the purpose of the methodology. One major limitation, compared with immunochemical screening, relates to the more complex data analysis.
